Physician profile
Fatima Hadi
NPI 1437222791
$3,143.54
in general payments reported to CMS, 2019-2025
23 companies · $420 in 2025
The $420 reported for 2025 was more than what a typical Child & Adolescent Psychiatry provider received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $502 · 2020: $147 · 2021: $288 · 2022: $260 · 2023: $872 · 2024: $655 · 2025: $420.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,947.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,947.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $407.34 | 2022-2025 | Caplyta |
| Supernus Pharmaceuticals, INC. | $405.29 | 2021-2025 | Qelbree, Qelbree |
| Otsuka America Pharmaceutical, INC. | $332.82 | 2019-2024 | Rexulti, Abilify Maintena |
| Corium, LLC | $293.32 | 2021-2025 | Azstarys |
| Ironshore Pharmaceuticals INC. | $199.58 | 2019-2024 | Jornay Pm |
| Axsome Therapeutics, INC. | $164.18 | 2023-2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $154.11 | 2020-2025 | Trintellix |
| Vanda Pharmaceuticals INC. | $151.92 | 2019-2025 | Hetlioz, Fanapt |
| Tris Pharma INC | $137.05 | 2019-2023 | Dyanavel Xr |
| Lundbeck LLC | $136.00 | 2020-2024 | Rexulti |
| Janssen Pharmaceuticals, INC | $127.16 | 2024 | Spravato |
| Neurocrine Biosciences, INC. | $100.55 | 2019-2023 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $94.43 | 2024-2025 | Uzedy |
| Idorsia Pharmaceuticals US INC | $65.73 | 2022-2023 | Quviviq |
| Sunovion Pharmaceuticals INC. | $63.59 | 2019-2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $56.44 | 2019 | |
| Neuronetics, INC. | $50.06 | 2023 | Neurostar Tms Therapy System |
| Collegium Pharmaceutical, INC. | $44.34 | 2025 | Jornay Pm |
| Almatica Pharma LLC | $40.64 | 2021 | |
| Vertical Pharmaceuticals, LLC | $34.37 | 2019 | |
| Adlon Therapeutics L.P. | $34.19 | 2019 | |
| Abbvie INC. | $27.90 | 2025 | |
| Alkermes, INC. | $22.53 | 2024 | Aristada, Lybalvi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fatima Hadi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.